MX340756B - Compuestos de quinazolina como inhibidores de serina/treonina quinasa. - Google Patents

Compuestos de quinazolina como inhibidores de serina/treonina quinasa.

Info

Publication number
MX340756B
MX340756B MX2014001389A MX2014001389A MX340756B MX 340756 B MX340756 B MX 340756B MX 2014001389 A MX2014001389 A MX 2014001389A MX 2014001389 A MX2014001389 A MX 2014001389A MX 340756 B MX340756 B MX 340756B
Authority
MX
Mexico
Prior art keywords
serine
kinase inhibitors
threonine kinase
quinazoline compounds
compounds
Prior art date
Application number
MX2014001389A
Other languages
English (en)
Spanish (es)
Other versions
MX2014001389A (es
Inventor
F Blake James
M Wallace Eli
Chen Huifen
Joseph Chicarelli Mark
Demeese Jason
Ferdinand Garrey Rustam
Gaudino John
Gazzard Lewis
J Kaus Robert
Klintz Samuel
J Mohr Peter
a moreno David
Schwarz Jacob
S Siedem Christopher
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2014001389A publication Critical patent/MX2014001389A/es
Publication of MX340756B publication Critical patent/MX340756B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2014001389A 2011-08-04 2012-08-03 Compuestos de quinazolina como inhibidores de serina/treonina quinasa. MX340756B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515165P 2011-08-04 2011-08-04
PCT/US2012/049551 WO2013020062A1 (en) 2011-08-04 2012-08-03 Quinazoline compounds as serine/threonine kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014001389A MX2014001389A (es) 2014-11-13
MX340756B true MX340756B (es) 2016-07-25

Family

ID=47003195

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001389A MX340756B (es) 2011-08-04 2012-08-03 Compuestos de quinazolina como inhibidores de serina/treonina quinasa.

Country Status (11)

Country Link
US (1) US9187462B2 (enExample)
EP (1) EP2739618B1 (enExample)
JP (1) JP6097289B2 (enExample)
KR (1) KR101979042B1 (enExample)
CN (1) CN103958502B (enExample)
BR (1) BR112014002675A2 (enExample)
CA (1) CA2844058A1 (enExample)
ES (1) ES2552989T3 (enExample)
MX (1) MX340756B (enExample)
RU (1) RU2014108140A (enExample)
WO (1) WO2013020062A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
CA2882750A1 (en) * 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
EP2909206A1 (en) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
CN103254142B (zh) * 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EA031243B1 (ru) 2013-12-06 2018-12-28 Дженентек, Инк. Ингибиторы серин/треонинкиназ
MX375902B (es) 2013-12-30 2025-03-07 Genentech Inc Inhibidores de serina/treonina cinasa.
KR102379517B1 (ko) * 2013-12-30 2022-03-25 제넨테크, 인크. 세린/트레오닌 키나아제 억제제
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
SG11202013175SA (en) 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN115243687A (zh) 2019-10-25 2022-10-25 默沙东有限责任公司 作为lrrk2抑制剂的n-(杂芳基)喹唑啉-2-胺衍生物、药物组合物及其用途
CN115448864B (zh) * 2022-08-26 2023-12-22 上海方予健康医药科技有限公司 3-氟-3-(1-羟乙基)吡咯烷-1-羧酸叔丁酯的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2274093C (en) 1996-12-05 2006-11-07 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
YU63802A (sh) 2000-02-25 2005-06-10 F. Hoffmann-La Roche Ag. Modulatori adenozinskih receptora
AU2001252606B2 (en) 2000-04-26 2005-07-07 Eisai R&D Management Co., Ltd. Medicinal compositions promoting bowel movement
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
MXPA04011470A (es) 2002-05-21 2005-02-14 Amgen Inc Compuestos heterociclicos sustituidos y metodos de uso.
WO2004007468A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
JP2007532669A (ja) 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリミジン
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2578122A1 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
EP1871762A2 (en) 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Erkインヒビターとしてのピロリジン誘導体
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de) 2006-07-29 2008-01-31 Lanxess Deutschland Gmbh Konservierungsmittel auf Basis von Carbonsäureanhydriden
CA2661334C (en) 2006-08-23 2011-11-29 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
MX2010005033A (es) 2007-11-06 2010-05-27 Du Pont Aminas heterociclicas fungicidas.
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
WO2009156484A2 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
PT2370413E (pt) 2008-12-08 2015-10-23 Arena Pharm Inc Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases

Also Published As

Publication number Publication date
EP2739618B1 (en) 2015-09-16
KR101979042B1 (ko) 2019-05-15
HK1199248A1 (zh) 2015-06-26
ES2552989T3 (es) 2015-12-03
US9187462B2 (en) 2015-11-17
JP2014521696A (ja) 2014-08-28
CN103958502A (zh) 2014-07-30
JP6097289B2 (ja) 2017-03-15
WO2013020062A1 (en) 2013-02-07
RU2014108140A (ru) 2015-09-10
US20150087664A1 (en) 2015-03-26
EP2739618A1 (en) 2014-06-11
HK1199021A1 (zh) 2015-06-19
BR112014002675A2 (pt) 2017-02-21
MX2014001389A (es) 2014-11-13
KR20140062057A (ko) 2014-05-22
CN103958502B (zh) 2016-02-10
CA2844058A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
HK1210174A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
PH12014500373A1 (en) Amino quinazolines as kinase inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX339873B (es) Inhibidores de serina/treonina cinasa.
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
AU2012250958A8 (en) Amino-pyridine-containing Spleen Tyrosine Kinase (Syk) inhibitors
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
PH12016501071A1 (en) Serine/threonine kinase inhibitors
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
WO2013003298A3 (en) Inhibitors of pde10
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
MX2012008141A (es) Compuestos y metodos.
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
PH12014500814A1 (en) New aryl-quinoline derivatives
PH12015501038A1 (en) Inhibitors of iap
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
WO2013155465A8 (en) Substituted xanthine derivatives
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.

Legal Events

Date Code Title Description
FG Grant or registration